Skip to main content
Journal cover image

Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.

Publication ,  Journal Article
Agwale, SM; Zeh, C; Robbins, KE; Odama, L; Saekhou, A; Edubio, A; Njoku, M; Sani-Gwarzo, N; Gboun, MS; Gao, F; Reitz, M; Hone, D; Wambebe, C ...
Published in: Vaccine
May 15, 2002

We conducted a national molecular epidemiologic survey of HIV-1 strains in Nigeria to determine the most prevalent subtype(s) for use in developing candidate vaccines. A total of 230 HIV-1-positive blood samples collected from 34 of the 36 Nigerian states were analyzed by our modified env gp41-based heteroduplex mobility assay (HMA) and/or gp41 sequencing and analysis. Overall, 103 (44.8%) were subtype A, 125 (54.3%) were subtype G, one (0.4%) was subtype C, and one (0.4%) was subtype J, and one (0.4%) was unclassifiable. To further characterize Nigerian viruses to aid in strain selection for candidate vaccines, one gp41 subtype G and five gp41 subtype A strains were selected for full envelope sequencing. The one subtype G sequence had consistent phylogenies throughout gp160, using programs to detect recombination. However, all five sequences that were primarily subtype A in gp41 were found to be recombinant viruses. Two of the five (40%) were A/G/J mosaics with common breakpoints. The remaining three gp160 recombinants all had their own unique break points: two A/? and one A/?/G, however, all five had the majority of their mosaic breakpoints occurring in gp41. None of the five were consistent with the circulating recombinant form (CRF)02_AG strain previously reported to be prevalent in West Africa. In conclusion, we showed a clear dominance and widespread distribution of gp41 subtypes A and G in fairly equal proportions, suggesting that vaccines designed for use in this geographic locale should incorporate the gene(s) of both subtypes. However, appreciating the magnitude of diversity of HIV-1 strains in Nigeria may require sequencing and analysis of longer gene regions for the identification of prevalent or emerging CRFs.

Duke Scholars

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

May 15, 2002

Volume

20

Issue

16

Start / End Page

2131 / 2139

Location

Netherlands

Related Subject Headings

  • Virology
  • Recombination, Genetic
  • Phylogeny
  • Nigeria
  • Humans
  • HIV-1
  • HIV Envelope Protein gp41
  • HIV Envelope Protein gp160
  • Clinical Trials as Topic
  • Amino Acid Sequence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Agwale, S. M., Zeh, C., Robbins, K. E., Odama, L., Saekhou, A., Edubio, A., … Kalish, M. L. (2002). Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine, 20(16), 2131–2139. https://doi.org/10.1016/s0264-410x(02)00059-2
Agwale, S. M., C. Zeh, K. E. Robbins, L. Odama, A. Saekhou, A. Edubio, M. Njoku, et al. “Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.Vaccine 20, no. 16 (May 15, 2002): 2131–39. https://doi.org/10.1016/s0264-410x(02)00059-2.
Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, Edubio A, et al. Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine. 2002 May 15;20(16):2131–9.
Agwale, S. M., et al. “Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.Vaccine, vol. 20, no. 16, May 2002, pp. 2131–39. Pubmed, doi:10.1016/s0264-410x(02)00059-2.
Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, Edubio A, Njoku M, Sani-Gwarzo N, Gboun MS, Gao F, Reitz M, Hone D, Pieniazek D, Wambebe C, Kalish ML. Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine. 2002 May 15;20(16):2131–2139.
Journal cover image

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

May 15, 2002

Volume

20

Issue

16

Start / End Page

2131 / 2139

Location

Netherlands

Related Subject Headings

  • Virology
  • Recombination, Genetic
  • Phylogeny
  • Nigeria
  • Humans
  • HIV-1
  • HIV Envelope Protein gp41
  • HIV Envelope Protein gp160
  • Clinical Trials as Topic
  • Amino Acid Sequence